FULGENT GENETICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
FULGENT GENETICS, INC. (FLGT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $868.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-30
- FULGENT GENETICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $516.00K, a 42.54% increase year-over-year.
- FULGENT GENETICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $352.00K, a 0.57% increase year-over-year.
- FULGENT GENETICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $567.00K, a 18.87% increase year-over-year.
- FULGENT GENETICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $485.00K, a 19.70% decline year-over-year.
- FULGENT GENETICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.76M, a 53.09% decline from fiscal 2024.
- FULGENT GENETICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $3.76M, a 41.36% decline from fiscal 2023.
- FULGENT GENETICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $6.41M, a 30.51% increase from fiscal 2022.
- FULGENT GENETICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $4.91M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $516.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $868.00K 10-Q · filed 2026-07-30 | $1.44M derived: sum of 3 quarters · filed 2026-07-30 | $1.92M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $352.00K 10-Q · filed 2026-05-01 | $919.00K derived: sum of 2 quarters · filed 2026-05-01 | $1.40M derived: sum of 3 quarters · filed 2026-05-01 | $1.77M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.05M derived: sum of 2 quarters · filed 2026-02-27 | $1.41M derived: sum of 3 quarters · filed 2026-07-30 | $1.76M 10-K · filed 2026-02-27 |
| 2025-09-30 | $485.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $847.00K derived: sum of 2 quarters · filed 2026-07-30 | $1.20M 10-Q · filed 2025-11-07 | $1.67M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $362.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $712.00K 10-Q · filed 2026-07-30 | $1.19M derived: sum of 3 quarters · filed 2026-07-30 | $1.79M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $350.00K 10-Q · filed 2026-05-01 | $827.00K derived: sum of 2 quarters · filed 2026-05-01 | $1.43M derived: sum of 3 quarters · filed 2026-05-01 | $2.60M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $477.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.08M derived: sum of 2 quarters · filed 2026-02-27 | $2.25M derived: sum of 3 quarters · filed 2026-02-27 | $3.76M 10-K · filed 2026-02-27 |
| 2024-09-30 | $604.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.77M derived: sum of 2 quarters · filed 2025-11-07 | $3.28M 10-Q · filed 2025-11-07 | $4.80M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $2.68M 10-Q · filed 2025-08-01 | $4.20M derived: sum of 3 quarters · filed 2026-02-27 | |
| 2024-03-31 | $1.51M 10-Q · filed 2025-05-02 | $3.03M derived: sum of 2 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.41M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $4.89M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $4.91M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |